Entero Therapeutics, Inc.
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
ENTO | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 777 YAMATO ROAD, 33431 BOCA RATON
- Website:
- https://enterothera.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, orally delivered therapies for gastrointestinal (GI) diseases. The company's product portfolio is built on its proprietary technologies, including latiglutenase, a biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for GI indications; and adrulipase, a recombinant lipase enzyme for exocrine pancreatic insufficiency. Entero's clinical programs target a range of digestive disorders, including celiac disease, gastroparesis, inflammatory bowel diseases, and conditions affecting patients with cystic fibrosis and chronic pancreatitis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Entero Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Entero Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Entero Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
